Hainan Haiyao forms JV with Xenios AG for ECMO technology

Hainan Haiyao Co., Ltd signed a joint venture agreement with Haikou National High-tech Industrial Development Zone Management Committee and Xenios AG to develop and produce ECMO-compatible products. Haiyao will invest RMB 200 million for a 45% stake, while Xenios AG will hold 40%.

“This strategic collaboration is aimed at developing and producing long-acting and short-acting membrane oxygenators, arteriovenous catheters, and other ECMO compatible products.”flcube.com

• 1 source
• flcube.comHainan Haiyao Enters JV with Haikou and Xenios AG to Advance ECMO Technology - Insight, China's Pharmaceutical IndustryFineline CubeNov 8, 2024

Summarized from public sources; check the original articles before acting on it.